2023年ASCO本土創(chuàng)新藥進(jìn)展跟蹤

《2023年ASCO本土創(chuàng)新藥進(jìn)展跟蹤》2023

ASCOHER2CDK4/6Publication

OnlyNeoadjuvantpyrotinibplus

trastuzumab,

dalpiciclib,

and

letrozole

for

triple-positive

breast

cancer:

A

pilot

trial.Pilot

Trial + + +/abstracts-presentations/224842Publication

OnlyPreliminaryanalysisofpyrotinibanddalpiciclib-basedtherapyinHER2-positiveadvancedbreastcancer

(ABC).HER2/abstracts-presentations/222842Poster

SessionUpdated

results

froma

phase

2

study

on

dalpiciclib

and

pyrotinib,

a

dual-oral

chemotherapy-free

regimen

in

HER2-positive

advanced

breast

cancer

(DAP-HER-01).II HER2 (DAP-HER-01)/abstracts-presentations/222583Poster

SessionPLEASURABLE:ResultsandbiomarkersanalysisfromthephaseIIstudyofdalpiciclibcombinedwithpyrotinibandendocrine

therapy

(ET)

in

w

omen

w

ith

dual-receptor

positive

(ER+/HER2+)metastatic

breast

cancer

(MBC).PLEASURABLE (II

) ER+/HER2+/abstracts-presentations/222584CDK4/6Publication

OnlyNeoadjuvantstereotactic

body

radiotherapy

plus

dalpiciclib

and

exemestanefor

hormone

receptor-positive,

HER2-negativebreast

cancer.HR+/HER2-/abstracts-presentations/22484332023

ASCOPD(L)1《2023年ASCO本土創(chuàng)新藥進(jìn)展跟蹤》SHR-1701PD-L1/TGF-βSHR-1701incombinationwithplatinum-basedchemotherapyandBP102(abevacizumabbiosimilar)

forPoster

Session persistent,

recurrent,

or

metastatic

cervical

cancer:

Data

froma

phase

1b/3

study.SHR-1701 BP102 Ib/III/abstracts-presentations/223074SHR-1701SHR2554PD-L1/TGF-βEZH2PhaseIstudyofthebifunctionalanti-PD-L1/TGF-βRIIagentSHR-1701combinedwithSHR2554,anEZH2

inhibitor,

in

patients

w

ith

previously

treated

advanced

lymphoma

and

solid

tumors.Oral

Abstract

Session SHR-1701(PD-L1/TGF-βRII ) SHR2554(EZH2 ) I/abstracts-presentations/220484Famitinibc-kit/VEGFR2/PDGFRβFamitinibforfamilialadenomatouspolyposis-associatedaggressivedesmoidtumors:A

single-centerPosterDiscussionSessionexploratory

study.Famitinib/abstracts-presentations/218434NANANAFUTURE-SUPER:

Arandomized,subtyping-basedumbrellaphaseIItrialforfirst-linetreatmentofPosterDiscussionSessionmetastatictriple-negativebreast

cancer.FUTURE-SUPER 1L

m

TNBC II/abstracts-presentations/222702NANANAA

prospective,

phase

II,

neoadjuvant

clinical

study

based

on

chemotherapy

sensitivity

inhormonePoster

Session receptor–positive,HER2-negativebreastcancer:FINEST

study.FINEST ( II

) HR+/HER2-/abstracts-presentations/2237732023

ASCO42023

ASCOPD(L)1《2023年ASCO本土創(chuàng)新藥進(jìn)展跟蹤》BTKPoster

SessionZanubrutinibplus

obinutuzumab

versus

obinutuzumab

inpatients

w

ith

relapsed/refractory

follicular

lymphoma:

UpdatedanalysisoftheROSEWOOD

study.ROSEWOOD (Obinutuzumab) //abstracts-presentations/220329Publication

OnlyMatching-adjustedindirectcomparison(MAIC)ofzanubrutinib(ZANU)versusibrutinib(IBRU)in

relapsed/refractorymarginalzonelymphoma(R/R

MZL).//abstracts-presentations/220704Publication

OnlyComparativeefficacy

ofzanubrutinib(ZANU)versusrituximab(RTX)inrelapsedmarginalzonelymphoma(MZL):Matching-adjustedindirectcomparison

(MAIC)./abstracts-presentations/220703Poster

SessionFirstinterim

analysis

of

a

phase

1

study

of

zanubrutinib

(zanu)

plus

lenalidomide

(len)

in

patients

(pts)

w

ithrelapsed/refractory

(R/R)

diffuse

large

B-cell

lymphoma

(DLBCL)./ B IPoster

Session/abstracts-presentations/220326MAHOGANY:Aphase3trialofzanubrutinibplusanti-CD20antibodiesvslenalidomideplusrituximabinpatientswithrelapsed

or

refractory

follicular

or

marginal

zonelymphoma.MAHOGANY

CD20III/abstracts-presentations/226007Publication

OnlyReal-w

orld

treatment

patterns

ofBruton

tyrosine

kinase

inhibitors

(BTKi)

in

patients

w

ith

mantlecell

lymphoma

(MCL)

incommunityoncologypracticesintheUnitedStates

(US).Bruton/abstracts-presentations/2207012023

ASCO52023

ASCOPD(L)1《2023年ASCO本土創(chuàng)新藥進(jìn)展跟蹤》BGB-11417bcl-2Poster

SessionA

phase

1

study

evaluatingthe

safety,

tolerability,

pharmacokinetics,

and

preliminary

antitumor

activity

of

Bcl-2

inhibitorBGB-11417inadult

patients

w

ith

mature

B-cell

malignancies.B Bcl-2 BGB-11417 I/abstracts-presentations/226689ZanidatamabHER-2Resultsfromthepivotalphase(Ph)2bHERIZON-BTC-01study:Zanidatamabinpreviously-treatedHER2-amplified

biliaryOral

Abstract

Sessiontract

cancer

(BTC).IIb

HERIZON-BTC-01 (Zanidatamab) HER2/abstracts-presentations/219904Zanidatamab

(zani),

a

HER2-targeted

bispecific

antibody,

in

combination

w

ith

docetaxel

as

first-line

therapy

(1L)

for

patients(pts)

w

ith

advanced

HER2-positive

breast

cancer

(BC):

Updated

results

froma

phase

1b/2

study.Poster

Session HER2 (Zanidatamab) HER2 Ib/II/abstracts-presentations/222572OciperlimabtigitPoster

SessionAdvanTIG-105:

A

phase

1b

dose-expansion

study

of

ociperlimab

(OCI)

+

tislelizumab(TIS)

w

ith

chemotherapy

(chemo)

inpatients

(pts)

w

ith

stage

IV

gastric/gastroesophageal

adenocarcinoma

(GC/GEJC).AdvanTIG-105 IV / Ib/abstracts-presentations/220977BGB-A445OX40Poster

SessionA

phase

1

study

of

theOX40

agonist,

BGB-A445,

w

ith

or

w

ithout

tislelizumab,

an

anti-PD-1

monoclonal

antibody,

inpatients

w

ith

advanced

solid

tumors.OX40 BGB-A445 BGB-A445 I/abstracts-presentations/2216812023

ASCO62023

ASCOPD(L)17《2023年ASCO本土創(chuàng)新藥進(jìn)展跟蹤》2023

ASCOPD(L)1SintilimabPD1PD-1blockadewithsintilimabplusinductionchemotherapyandconcurrentchemoradiotherapy(IC-CCRT)versus

IC-CCRTinlocoregionally-advancednasopharyngealcarcinoma(LANPC):Amulticenter,phase3,randomized

controlledOral

Abstract

Session

trial(CONTINUUM).CONTINUUM

III

RCT NPC/abstracts-presentations/218513IBI-126CEACAM5ADCPhase1/2

study

of

tusamitamab

ravtansine

in

patients

w

ith

advanced

solid

tumors:

Pooled

safety

analysis

of

cornealPublication

Only adverse

events.tusamitamab

ravtansine I/II/abstracts-presentations/225033IBI-351KRAS

G12CEfficacy

and

safety

ofIBI351

(GFH925)

monotherapy

in

metastatic

colorectal

cancer

harboring

KRASG12C

mutation:Poster

Session Preliminary

results

froma

pooled

analysis

of

tw

o

phase

I

studies.I pooled

analysis：IBI351(GFH925) KRASG12C m

CRC/abstracts-presentations/224381IBI-110LAG-3Efficacy

and

safety

ofIBI110

in

combination

w

ith

sintilimab

and

lenvatinib

in

first-line

ofadvanced

hepatocellularPoster

Session carcinoma:PreliminaryresultsfromaphaseIb

study.Ib :

IBI110(LAG3) 1L

HCC

/abstracts-presentations/221705Efficacy

and

safety

ofIBI110

in

combination

w

ith

sintilimab

in

first-line

advanced

HER2-negative

gastric

cancer

orPoster

Session gastroesophageal

junction

cancer:

Updated

results

froma

phase

Ib

study.Ib IBI110(LAG3) HER2 1L

GC/GEJ/abstracts-presentations/221703IBI-939TIGITA

study

to

evaluate

the

safety,

tolerability,

and

efficacy

ofIBI939

in

combination

w

ith

sintilimab

in

patients

w

ith

previouslyuntreatedlocallyadvancedunresectableormetastaticPD-L1–selectednon–small-celllungcancer(NSCLC):UpdatedPublication

Only efficacy

and

safety

results.IBI939(TIGIT) PD-L1NSCLC/abstracts-presentations/224941CT103ABCMACAR-TCT103A,anovelfullyhumanBCMA-targetingCAR-Tcells,inpatientswithrelapsed/refractorymultiplemyeloma:UpdatedPoster

Session results

of

phase

1b/2

study

(FUMANBA-1).Ib/II

FUMANBA-1 CT103A(BCMA

CART) R/R

MM/abstracts-presentations/2238062023

ASCO《2023年ASCO本土創(chuàng)新藥進(jìn)展跟蹤》AK104PD-1/CTLA-4A

phase

Ib/II,

multicenter,

open-label

study

of

AK104,

a

PD-1/CTLA-4

bispecific

antibody,

combinedw

ith

chemotherapyPoster

Session

(chemo)

as

first-line

therapy

for

advanced

gastric

(G)

or

gastroesophageal

junction

(GEJ)

cancer:

2-Year

update

data.Ib/II AK104(PD-1/CTLA-4 ) 1L

GC/GEJ/abstracts-presentations/221006A

study

of

cadonilimab

combinedw

ith

regorafenib

as

second-line

or

later

therapy

in

patients

w

ith

advanced

hepatocellularPublicationOnlycarcinoma

(aHCC).AK104 2L+

HCC/abstracts-presentations/222094The

safety

and

efficacy

of

cadonilimab

in

the

treatment

ofadvanced

and

metastatic

cervical

cancer:

A

retrospective,

real-PublicationOnlyworld

study.AK104/abstracts-presentations/223472AK112PD-1/VEGFPhaseIIresultsofivonescimab(AK112/SMT112),anovelPD-1/VEGFbispecific,incombinationwithchemotherapyforfirstlinetreatmentofadvancedormetastaticnon-smallcelllungcancer(NSCLC)withoutactionable

genomicalterationsPosterSession(AGA)in

EGFR/ALK.II AK112(SMT112) EGFR/ALK 1L

NSCLC/abstracts-presentations/218931AK117CD47The

safety

and

efficacy

of

cadonilimabin

combination

w

ith

AK117

(anti-CD47

antibody)

plus

chemotherapy

as

first-linePublicationOnlytreatmentforadvancedgastric(G)orgastroesophagealjunction

(GEJ)cancer.AK104 AK117(CD47) 1L

GC/GEJ/abstracts-presentations/2221532023

ASCO82023

ASCOPD(L)1《2023年ASCO本土創(chuàng)新藥進(jìn)展跟蹤》PD-1FinaloverallsurvivalandbiomarkeranalysesofCHOICE-01:

Adouble-blindrandomizedphase3studyoftoripalimabversus

placebo

in

combination

chemotherapy

for

advanced

NSCLC

w

ithout

EGFR/ALK

mutations.OralAbstract

Session

CHOICE-01 EGFR/ALK NSCLCIII/abstracts-presentations/226664Perioperativetoripalimab+platinum-doubletchemotherapyvschemotherapyinresectablestageII/IIInon-smallcell

lungOral

Abstract

Session

cancer

(NSCLC):

Interim

event-free

survival

(EFS)

analysis

of

the

phase

III

NEOTORCH

study.II/III

NSCLC + III

NEOTORCH EFS/abstracts-presentations/219867PerioperativePD-1antibodytoripalimabplusSOXorXELOXchemotherapyversusSOXorXELOXaloneforlocallyadvanced

gastric

or

gastro-oesophageal

junction

cancer:

Results

froma

prospective,

randomized,

open-label,

phase

IIOral

Abstract

Session

trial.PD-1 SOX

XELOX SOX

XELOXII/abstracts-presentations/219777Temozolomidepluscisplatinversustoripalimab(anti-PD-1)asadjuvanttherapyinresectedmucosal

melanoma.OralAbstract

Session/abstracts-presentations/226520TifcemalimabBTLAPosterSessionPhaseI/IIcombination

study

of

tifcemalimab

w

ith

toripalimab

in

patients

w

ith

refractory

extensive

stage

small

cell

lungcancer

(ES-SCLC).Tifcemalimab (ES-SCLC) I/II/abstracts-presentations/2231092023

ASCO92023

ASCOPD(L)1《2023年ASCO本土創(chuàng)新藥進(jìn)展跟蹤》RC48 HER-2 ADCAmulticenter,phaseIItrialofRC48-ADCcombinedwithradiotherapy,PD-1/PD-L1inhibitor,GM-CSF,andsequential

IL-2(PRaG3.0

regimen)for

salvage

therapy

in

patients

w

ith

HER2-expressing

advanced

solid

tumors.Publication

Only II RC48 PD-1/PD-L1

GM-CSF IL-2(PRaG3.0 ) HER2/abstracts-presentations/224610Disitamabvedotin,anovelhumanizedanti-HER2antibody-drugconjugate(ADC),combinedwithtoripalimabinpatientsPoster

Session w

ith

locally

advanced

or

metastatic

urothelial

carcinoma:

An

open-label

phase

1b/2

study.Ib/II RC48

toripalimab UC/abstracts-presentations/219962SKB-264TROP2ADCPosterSessionSKB264(TROP2-ADC)for

thetreatment

ofpatients

w

ith

advanced

NSCLC:

Efficacy

and

safety

data

froma

phase

2study.SKB264(TROP2-ADC) NSCLC II/abstracts-presentations/218898KL590586RETOralAbstract

SessionA

phase

I

study

ofKL590586,

anext-generation

selective

RET

inhibitor,

in

patients

w

ith

RET-altered

solid

tumors.RET KL590586

RET I/abstracts-presentations/2199572023

ASCO102023

ASCOPD(L)1《2023年ASCO本土創(chuàng)新藥進(jìn)展跟蹤》Cilta-cel BCMA CARTCARTITUDE-1

final

results:

Phase1b/2

study

of

ciltacabtagene

autoleucel

in

heavily

pretreated

patients

w

ithPosterDiscussionSessionrelapsed/refractorymultiple

myeloma.CARTITUDE-1 Cilta-cel

R/R

MM Ib/II/abstracts-presentations/221911Long-term

remission

and

survival

inpatients

w

ith

relapsed

or

refractory

multiple

myeloma

after

treatment

ofPosterDiscussionSession

LCAR-B38MCAR-T:Atleast5-yearfollow-upinLEGEND-2.LEGEND-2 5 Cilta-cel R/R

MM/abstracts-presentations/218472Firstphase

3

results

from

CARTITUDE-4:

Cilta-cel

versus

standard

ofcare

(PVd

or

DPd)

in

lenalidomide-ClinicalScienceSymposiumrefractorymultiple

myeloma.CARTITUDE-4 III Cilta-cel (PVd

DPd) MM/abstracts-presentations/220015Safety

and

efficacy

ofstandard

ofcare

(SOC)

ciltacabtagene

autoleucel

(Cilta-cel)

for

relapsed/refractoryPosterDiscussionSessionmultiplemyeloma

(RRMM).Cilta-cel R/R

MM/abstracts-presentations/219990GC012FBCMA/CD19CARTPoster

SessionUpdated

clinical

results

of

first-in-human

study

of

CD19/BCMA

dual-targeting

fast

CAR-T

GC012Ffor

patientsw

ith

relapsed/refractory

B-cell

non-Hodgkin’s

lymphoma.FIH GC012F(CD19/BCMA FastCAR-T) R/R

B-cell

nHL/abstracts-presentations/220336OralAbstract

SessionUpdatedresultsofaphaseI,open-labelstudyofBCMA/CD19dual-targetingfastCAR-TGC012Ffor

patientswithrelapsed/refractory

multiplemyeloma(RRMM).I GC012F(CD19/BCMA FastCAR-T) R/RMM

I/abstracts-presentations/2228012023

ASCO112023

ASCOPD(L)1《2023年ASCO本土創(chuàng)新藥進(jìn)展跟蹤》KN046KN026PD-L1/CTLA-4HER2Poster

SessionEfficacy

and

safety

ofKN026

incombination

w

ith

KN046

inpatients

w

ith

locally

advanced

unresectable

ormetastaticHER2-positiveothersolid

tumors.KN026

KN046

HER2/abstracts-presentations/224331APG-2449FAK/ALK/ROS1FAK

inhibition

w

ith

novel

FAK/ALK

inhibitor

APG-2449

could

overcome

resistance

in

NSCLC

patients

w

ho

arePosterDiscussionSession

resistanttosecond-generationALKinhibitors.FAK/ALK APG-2449 FAK (NSCLC) ALK/abstracts-presentations/220379HQP1351BCR-ABL/KITPoster

SessionAntitumoractivityofolverembatinib(HQP1351)inpatients(pts)withtyrosinekinase

inhibitor(TKI)–resistantsuccinate

dehydrogenase

(SDH)–deficient

gastrointestinal

stromal

tumor

(GIST).(HQP1351) (TKI) (SDH-deficientGIST)/abstracts-presentations/220666APG-2575Bcl-2Poster

SessionPreliminarydataofaphase1b/2studyofBCL-2inhibitorlisaftoclax(APG-2575)aloneorcombinedw

ithibrutiniborrituximabinpatients(pts)withWaldenstr?mmacroglobulinemia

(WM).Bcl-2 APG-2575 (WM) Ib/II/abstracts-presentations/220353APG115MDM2-p53Poster

SessionA

phase

2

study

of

alrizomadlin

(APG-115)

in

combination

w

ith

pembrolizumab

inpatients

w

ith

unresectable

ormetastaticcutaneousmelanomathathasfailedimmuno-oncologic(IO)drugs.II APG-115 (IO)/abstracts-presentations/2201952023

ASCO122023

ASCOPD(L)1《2023年ASCO本土創(chuàng)新藥進(jìn)展跟蹤》TTFOralAbstract

SessionTumorTreatingField(TTFields)therapywithstandardofcare(SOC)inmetastaticnon-smallcelllungcancer(mNSCLC)

followingplatinumfailure:Randomized,phase3LUNARstudy.III

LUNARm

NSCLC/abstracts-presentations/219192OnatasertibTORC1/2Aphase1/2studyoftheTORC1/2inhibitoronatasertibcombinedwithtoripalimabinpatientswith

advancedPosterDiscussionSessionsolid

tumors.TORC1/2 onatasertibI/II/abstracts-presentations/220486HBM-4003CTLA-4Publication

OnlyA

phase

Ib

study

ofporustobart

(HBM4003),

ananti-CTLA-4

heavy

chain

only

monoclonal

antibody,

incombination

w

ith

toripalimabinpatients

w

ith

hepatocellular

carcinoma.Porustobart(HBM4003 CTLA-4 ) toripalimab HCC

Ib/abstracts-presentations/2220772023

ASCO132023

ASCOPD(L)1《2023年ASCO本土創(chuàng)新藥進(jìn)展跟蹤》HS-10382BCR-ABLPoster

SessionA

phase

1,

multicenter,

open-label,

dose-escalation

and

dose-expansion

study

to

evaluate

thesafety,

tolerability,pharmacokinetics(PK),andefficacyofHS-10382(TERN-701)inpatients(pts)withchronicmyeloidleukemia(CML).I HS-10382(TERN-701)

CMLPK/abstracts-presentations/225981HS-10241c-METPublication

OnlyPhase

1b

study

ofHS-10241

combined

w

ith

almonertinib

in

pre-treated

advanced

non-small

cell

lung

cancer(NSCLC)harboringEGFR

mutation.HS-10241 EGFRmtNSCLC

Ib/abstracts-presentations/219129ALMB-0168Cx43Poster

SessionALMB-0168,a

novel

Cx43hemichannel

agonistmonoclonal

antibody,

for

metastatic

or

unresectable

osteosarcomaafter

standard

chemotherapy:

A

multicenter,open-label,

single-arm,

phase

1

study.I ALMB-0168( Cx43 )I/abstracts-presentations/220630SYA1801Claudin

18.2ADCFirst-in-human

dose

escalation

and

expansion

study

of

SYSA1801,

an

antibody-drug

conjugate

targeting

claudinPosterDiscussionSession

18.2inpatientswithresistant/refractorysolidtumors.FIH SYSA1801(CLDN18.2

ADC) //abstracts-presentations/2217642023

ASCO142023

ASCOPD(L)1《2023年ASCO本土創(chuàng)新藥進(jìn)展跟蹤》QL1706PD1/CTLA4Poster

SessionAnopen-label,multicenter,adaptive,phaseIb/II

studyofQL1706orQL1604plusbevacizumabasfirst-linetreatmentin

patients

w

ith

advanced

hepatocellular

carcinoma.QL1706

QL1604 1L

HCC Ib/II/abstracts-presentations/220956Poster

SessionA

randomized,

doubleblinded,

multicenter

phase

3

study

ofplatinum-based

chemotherapy

w

ith

or

w

ithout

QL1706asadjuvanttherapyincompletelyresectedstageII-IIIb

NSCLC.III QL1706 II-IIIb

NSCLC/abstracts-presentations/226025Poster

SessionSafety

and

efficacy

ofQL1706

plus

carboplatin/etoposide

(EC)

as

first-line

(1L)

treatment

for

extensive-stage

small-celllungcancer(ES-SCLC):TheresultsfromaphaseIIsingle-arm

study.II QL1706 / (EC) 1L

ES-SCLC/abstracts-presentations/223133Poster

SessionAphaseIII,multicenter,double-blinded,randomized,active-controlledstudyontheefficacyandsafetyofQL1706w

ith

chemotherapy

(CT)

as

first-line

therapy

for

PD-L1–negative

advanced

or

metastatic

non–small-cell

lung

cancer(NSCLC).III

RCT QL1706 1L

PD-L1 NSCLC/abstracts-presentations/226050CDK4/6Neoadjuvantsingle-dosetrilaciclibpriortocombinationchemotherapyinpatientswithearlytriple-negativebreastPoster

Session cancer:

Safety,

efficacy,

and

immune

correlate

data

froma

phase

2

study.trilaciclib II/abstracts-presentations/223763Real

w

orld

outcomes

of

trilaciclib

inES-SCLC.Publication

Only trilaciclib

ES-SCLC/abstracts-presentations/2236492023

ASCO152023

ASCOPD(L)1《2023年ASCO本土創(chuàng)新藥進(jìn)展跟蹤》VEGFR1/2/3Publication

OnlyFruquintinib

versus

fruquintinib

combined

w

ith

PD-1

inhibitors

for

metastatic

colorectal

cancer:

Real-w

orld

data.PD-1 m

CRC/abstracts-presentations/225295Publication

OnlyA

phase

IV

study

to

evaluate

the

safety

of

fruquintinib

in

Chinese

real-w

orld

clinical

practice.IV/abstracts-presentations/225245Poster

SessionAnalysis

of

fruquintinib

adverse

events

of

special

interest

fromphase

3

of

the

FRESCO-2

study.III

FRESCO-2/abstracts-presentations/224409Publication

OnlyPhaseII

study

of

fruquintinibas

second

or

further-line

therapy

for

patients

w

ith

advanced

biliary

tract

cancer.2L+ II/abstracts-presentations/222117Publication

OnlyA

phase

II

study

of

fruquintinib

in

the

first-

(1L)

or

second-line

(2L)

treatment

ofunresectable

metastatic

softtissue

sarcoma.1L

2L II/abstracts-presentations/220855Publication

OnlyQuality

of

life,effectiveness,

and

compliance

of

fruquintinib

in

the

treatment

of

metastatic

colorectal

cancer:Results

froma

prospective

real-world

study.mCRC

QoL/abstracts-presentations/225219Publication

OnlyFruquintinib

plus

oxaliplatin

combined

w

ith

S-1

(SOX)

as

neoadjuvanttherapy

for

locally

advanced

gastricadenocarcinoma(FRUTINEOGA):Amulticenter,phaseII

study.S-1(SOX)

(FRUTINEOGA) II/abstracts-presentations/2220052023

ASCO162023

ASCOPD(L)1《2023年ASCO本土創(chuàng)新藥進(jìn)展跟蹤》VEGFR1/2/3Publication

OnlyA

phase

Ⅰ/Ⅱa

study

ofcetuximab

combined

w

ith

fruquintinib

in

the

previously

treated

RAS/BRAF

w

ild-typemetastaticcolorectalcancer:ResultsoftheCEFRU

study.CEFRURAS/BRAFwtmCRC

I/IIa/abstracts-presentations/225222Poster

SessionEfficacy

and

safety

of

fruquintinib

plus

investigator's

choice

of

chemotherapy

as

second-line

therapy

in

metastaticcolorectal

cancer:

A

multicenter,

single-arm

phase

2trial.2L

m

CRCII/abstracts-presentations/224368Poster

SessionSubgroup

analyses

ofsafety

and

efficacy

by

number

and

types

of

prior

lines

of

treatment

in

FRESCO-2,

aglobalphase

III

study

of

fruquintinib

in

patients

w

ith

refractory

metastatic

colorectal

cancer.FRESCO-2( III )/abstracts-presentations/224411Publication

OnlyFruquintinibplussintilimabinpatientswitheithertreatment-naiveorpreviouslyfirstlinetreatedmetastaticclear-cell

renal

cell

carcinoma

(ccRCC):Results

from

a

multicenter,

single-arm

phase

2

study.Fruquintinib

sintilimab 1L (ccRCC)II/abstracts-presentations/222340HMPL-453FGFR1/2/3Publication

OnlyAphase2studyofHMPL-453,aselectiveFGFRtyrosinekinaseinhibitor(TKI),inpatientswithpreviouslytreatedadvancedcholangiocarcinomacontainingFGFR2

fusions.HMPL-453(

FGFR

TKI)

FGFR2II/abstracts-presentations/222135EZH2Poster

SessionTazemetostat,aselectiveEZH2inhibitor,withpembrolizumabastreatmentofanti-PD-1resistantheadandnecksquamous-cellcarcinoma(HNSCC):Aphase1-2

trial.I-II Tazemetostat( EZH2 ) pembrolizumab PD1 HNSCC/abstracts-presentations/2185322023

ASCO172023

ASCOPD(L)1《2023年ASCO本土創(chuàng)新藥進(jìn)展跟蹤》A

multicenter,single-arm,phase

2

study

of

surufatinib

plus

toripalimab

for

patients

w

ith

advanced

endometrialPosterSession

cancer.II/abstracts-presentations/223054A

phase

II

study

of

surufatinib

inpatients

w

ith

osteosarcoma

and

soft

tissue

sarcoma

w

ho

have

experiencedPublicationOnly

treatmentfailurewithstandardchemotherapy.II/abstracts-presentations/220845A

phase

1b/2

study

of

surufatinib

plus

camrelizumab,

nab-paclitaxel,

and

S-1(NASCA)

as

first-line

therapy

formetastaticpancreaticadenocarcinoma

(mPDAC).Poster

Session S-1(NASCA) (mPDAC)1L Ib/IIVEGFR1/2/3;FGFR1;CSF-1R /abstracts-presentations/226583A

phase

Ib/II

study

to

evaluate

surufatinib

combinedw

ith

camrelizumab

and

chemotherapy

in

the

second-linePosterSession

treatmentofadvancedcolorectalcancer:PhaseIbresults.camrelizumab 2L

CRCIb/II Ib/abstracts-presentations/224337A

multicenter,

single-arm

phase

2

study

of

surufatinib

plus

toripalimab

for

patients

w

ith

locally

advanced

orPosterSession

metastaticradioactiveiodine-refractorydifferentiatedthyroidcancer.II/abstracts-presentations/218570Phase1b/2

study

of

surufatinib

in

combination

w

ith

docetaxel

as

second-line

treatment

of

advanced

driver-genePublicationOnlynegativenon-squamousnon-smallcelllungcancer

(NSCLC).2LnsqNSCLC

Ib/II/abstracts-presentations/2190192023

ASCO182023

ASCOPD(L)1《2023年ASCO本土創(chuàng)新藥進(jìn)展跟蹤》ZalifrelimabCTLA-4OralAbstract

SessionA

single-arm,

open-label

phase

2

trial

of

doxorubicin

plus

zalifrelimab,

a

CTLA-4

inhibitor,

w

ith

balstilimab,

aPD-1

inhibitor,

inpatients

w

ith

advanced/metastatic

soft

tissue

sarcomas.CTLA-4 zalifrelimab

PD-1 balstilimab /II/abstracts-presentations/218377BPI-16350CDK4/6Publication

OnlyBPI-16350,anovelpromisingCDK4/6inhibitorforHR+/HER2-

metastaticbreastcanc